Pfizer buys Exubera from Sanofi-Aventis for $1.3B.
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Pfizer |
Sanofi-Aventis |
$1.3B buyout |
Pfizer will buy out Sanofi-Aventis' interest in Exubera, an inhaled, dry powder form of human insulin that they were jointly developing. |
|
Perlegen |
Genentech |
collaboration deal |
The companies will study the genetics of cancer and hope to develop new therapies and diagnostic tools for the disease. |
|
KAI Pharmaceuticals |
Daiichi Sankyo |
$340M licensing deal |
The deal is for KAI-9803, a treatment to reduce the damage caused by reperfusion during angioplasty. |
|
Avigen |
Sanochemia Pharmazeutika |
$100M licensing deal |
The deal is for a brain spasm drug. |
|
Forest |
Mylan |
$75M licensing deal |
Forest will pay Mylan for the development rights to the hypertension drug nebivolol in the U.S. and Canada. |
|
CancerVax |
Micromet |
$126. 7M merger |
CancerVax has agreed to team up with Germany's Micromet in a buyout. |
|
Connetics |
PediaMed Pharmaceuticals |
$12.5M acquisition |
Connetics will acquire the sales organization of PediaMed. |
|
Becton, Dickinson |
GeneOhm Sciences |
buyout |
Becton, Dickinson is buying GeneOhm Sciences for $230M and $25M in incentive payments; GeneOhm makes infection tests. |
|
Affymetrix |
Duke University |
collaboration deal |
Duke researchers will use Affymetrix's GeneChip microarray technology to look for RNA and DNA patterns that can be used to classify and treat cardiovascular and cancer disease. |